Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
IPO Year:
Exchange: NASDAQ
Website: markertherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/17/2022 | $3.00 → $1.00 | Buy → Neutral | Roth Capital |
SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)
SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)
SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)
3 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% to $2.71. The company's market cap stands at $117.6 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 21.69% to $2.3. The market value of their outstanding shares is at $89.7 million. Heart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 12.87% to $5.81. The company's market cap stands at $3.8 million. I-MAB (NASDAQ:IMAB) shares increased by 12.23% to $2.11. The company's market cap stands at $170.6 million. Agenus (NASDAQ:AGEN) stock
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.27) per share. This is a 52.63 percent increase over losses of $(0.57) per share from the same period last year. The company reported $1.24 million in sales this quarter. This is a 0.79 percent increase over sales of $1.23 million the same period last year.
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $11.
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.Reported A Net Loss Of $8.2 Million For The Year Ended December 31, 2023, Compared To A Net Loss Of $29.9 Million
Marker Therapeutics Inc (NASDAQ:MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. The company has prioritized MT-601 in chimeric antigen receptor (CAR) relapse patients with lymphoma. The FDA cleared Marker's Investigational New Drug application for a Phase 1 trial to investigate MT-601 combined with first-line chemotherapy in patients with pancreatic cancer. The clinical advancement of this multicenter study will be pending additional funding from non-dilutive sources. In addition, the company reported a clinical update on the Phase 2 ARTEMIS study of MT-401 for acut
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares moved upwards by 60.0% to $0.88 during Friday's after-market session. The company's market cap stands at $30.8 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 18.15% to $0.19. The company's market cap stands at $29.6 million. Cadrenal Therapeutics (NASDAQ:CVKD) shares moved upwards by 9.67% to $0.78. The company's market cap stands at $10.1 million. GlucoTrack (NASDAQ:GCTK) stock moved upwards by 8.98% to $0.28. The company's market cap stands at $5.9 million. Monopar Therapeutics (NASDAQ:MNPR) stock increased by 8.82% to $0.37. The market value of their outstanding shares is at $5.5 million. NGM Biopharmaceuticals (NASDAQ:NGM
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The SBIR grant has been awarded based in part on Marker's preliminary clinical data
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin's Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment Company received approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for "neldaleucel" as nonproprietary name for MT-601 HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunother
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024. Dr. Vera will present an overview of Marker's advancements and clinical development programs on Tuesday, March 26, 2024, at 10 AM EDT. Details of the presentation are as follows: Event:H.
Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company's Board of Directors. Dr. Knobil is a seasoned executive with more than 20 years of experience in pharmaceutical research and product development including global clinical research, medical affairs, and patient safety. "We are honored to welcome Dr. Knobil to our Board of Directors as we embark on the next exciting chapter at Nimbus with plans to accelerate and expand our development programs in multiple ther
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, announced today that the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved "neldaleucel" as the nonproprietary (generic) name for MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product candidate for the treatment of patients with lymphoma. The USAN Council in close collaboration with the WHO established INN exp
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the Company's management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit. Both events will be held in-person and are scheduled alongside the J.P. Morgan 42nd Annual Healthcare Conference 2024. Details of the events are as follows: Event:Biotech ShowcaseDate:January 8-10, 2024Location:Hilton San Francisco Union SquareRegistration:https://informaconnect
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (zedenoleucel) for the treatment of patients with Acute Myeloid Leukemia (AML) Demonstrated enhanced anti-tumor activity in an aggressive, treatment-resistant AML cell line and provided an update on clinical readiness of the MT-401 Off-the-Shelf (OTS) program HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based i
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Dr. Vera will provide an overview of Marker's advancements and clinical development programs on Wednesday, September 13, 2023, at 8:30 a.m. EDT. Of note, Marker believes i
Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously
Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of Marker International with a rating of Overweight and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00
Oppenheimer resumed coverage of Marker Therapeutics with a rating of Buy and set a new price target of $8.00
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)
ARS - Marker Therapeutics, Inc. (0001094038) (Filer)
DEF 14A - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St
Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company's Board of Directors. Dr. Knobil is a seasoned executive with more than 20 years of experience in pharmaceutical research and product development including global clinical research, medical affairs, and patient safety. "We are honored to welcome Dr. Knobil to our Board of Directors as we embark on the next exciting chapter at Nimbus with plans to accelerate and expand our development programs in multiple ther
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer. Dr. Stuart brings more than 20 years of experience as a clinician-scientist and drug developer to Marker Therapeutics where she will be responsible for advancing the development of multi-tumor associated antigen (multiTAA)-specific T cell product pipeline, including the ongoing MT-401 Phase 2 ARTEMIS clinical study and Phase 1 clinical st
Structured To Extend Marker's Financial Runway Through Year-End 2025 Marker Announces Leadership Transition & Provides Update on Operational Strategy HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has entered into a comprehensive agreement with CellReady™, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, founder and CEO of Wilson Wolf Corporation and Marker Co-Founder and Board Member. Under the term
Enrollment of first 20 patients of the Company's Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2021. "In
HOUSTON, Dec. 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Katharine Knobil, M.D., to the Company's Board of Directors. "We are excited to announce the appointment of Dr. Knobil to the Board of Directors," said Peter L. Hoang, President & CEO of Marker. "Dr. Knobil's extensive leadership experience in clinical development of new
Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68
HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu